Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Otsuka Targets Around 2030 US Launch for Transcend’s PTSD Candidate
Otsuka Pharmaceutical is aiming to launch its newly acquired post-traumatic stress disorder (PTSD) drug candidate TSND-201 in the US around 2030, with peak sales expected to exceed 100 billion yen, a senior executive said. Speaking at an April 10 briefing…
To read the full story
Related Article
- Otsuka Closes US$700 Million Transcend Buyout
June 16, 2026
- Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
BUSINESS
- GSK Hit with MHLW Guidance over Sponsored Lecture
September 2, 2026
- Nonprescription Cialis Goes Nationwide in Japan, Now at 10,000 Outlets
September 2, 2026
- Veloxis Starts US PII Study of Novel Immunosuppressant
September 2, 2026
- Canada Backs Public Reimbursement of Leqembi
September 2, 2026
- Marubeni Pharma Sets Up Hong Kong Subsidiary
September 2, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…